Tokenized Private Asset Products: Synthetic vs Backed

Private companies now hold more value than at any point in history, and most investors cannot touch it. The US exempt-offering market raises more capital each year than registered offerings, according to SEC data on exempt offerings. Into that gap come tokens promising exposure to private companies, funds and real assets. Some are claims on the asset. Others are derivatives that only track a price. On a wallet screen they look the same, and that is the problem institutions need to solve before they allocate.

Two products that look identical and are not

A backed token represents a legal interest in something that exists: shares or units held by a special purpose vehicle, a fund interest, a royalty stream, a fractional claim on a building. The issuer holds the underlying position, and the token is the record of who owns the economic claim.

A synthetic token is a contract. It pays out based on a reference price, usually an estimate of what a private company is worth, and no shares sit behind it. The buyer holds an obligation from the issuer or a protocol, not an ownership interest in the company.

Both can be legitimate. Synthetic exposure has a long history in capital markets, from swaps to futures. The risk is not the structure. The risk is a buyer who believes they hold the first when they hold the second. A pre-IPO token marketed with a company's name, priced off secondary-market chatter, is a derivative on a number that nobody publishes in a verifiable way.

The test is simple to state: if the issuer disappeared tomorrow, what could you point to that you own?

A five-point checklist for any tokenized private asset

Institutions already run diligence on private funds. The same discipline applies to tokenized products, with a few on-chain additions.

1. Legal claim on the asset. Identify the entity that holds the underlying position, the document that gives the token holder rights against it, and whether those rights survive the issuer's insolvency. A backed structure should show a ring-fenced vehicle and a clear chain from token to asset. A synthetic should state plainly that it is an unsecured contractual obligation.

2. Custody and reserve attestation. Backed claims should be verifiable against something. For commodities and funds, that means independent custody and periodic or continuous attestation that reserves match tokens outstanding. Our explainer on proof of reserve for RWAs covers how this works, including how on-chain data feeds can publish reserve figures that a counterparty can query rather than take on trust. A product with no reserve evidence is asking for a claim to be believed.

3. Transfer restrictions. Private securities are restricted by design. Resale limits, lockups and holder caps travel with the security, and a token that ignores them is either not the security or not consistent with it. Check whether restrictions are enforced in the token contract itself or only described in a PDF.

4. Investor eligibility. Who may buy, and who verified it? Offerings under Regulation D generally require accredited investors, while Regulation S covers offshore sales to non-US persons, both described on the SEC exempt offerings page. A product open to anyone with a wallet is not operating inside either framework, which tells you something about what it actually is.

5. Dispute venue. If the issuer, custodian and buyer disagree, where is it resolved, under which law? Backed issuances usually name a court or arbitration seat in a recognized jurisdiction. Synthetic protocols often name nothing, or a foundation with no assets.

Scoring a synthetic pre-IPO token against a Reg D or Reg S issuance

Run both through the same five questions and the difference becomes concrete.

A Regulation D issuance holding private company shares in an SPV scores well on the first four points by construction. There is a legal claim, a custodian or transfer agent, restrictions inherited from the underlying shares, and a verified investor base. Its weak spot is usually liquidity and price discovery, not structure. Holders own something real but may wait for a venue to trade it.

A Regulation S issuance sold offshore scores similarly on claim and restrictions but adds a jurisdiction question: the buyer pool, the resale lockup period and the venue need to line up so that tokens do not flow back to US persons before they are allowed to.

A synthetic pre-IPO token tends to score well on one thing, accessibility, and poorly on the rest. There is no claim on the shares, reserve attestation has nothing to attest, eligibility is loose and the dispute venue is vague. That is the trade: easy access in exchange for a weaker claim. For a retail speculator that may be an informed choice. For an institution with a fiduciary duty, it is a position that needs to be sized and disclosed as a derivative.

The broader point is that tokenization is one layer of the stack. A token improves record-keeping, transfer and settlement speed. It does not turn a derivative into an asset. The underlying legal wrapper does that work, which is why our overview of what RWA tokenization is starts with the claim and ends with the ledger, not the other way around.

The question the marketing skips: what happens at the IPO

Every synthetic pre-IPO product has a moment of truth. The referenced company lists, and a real price appears on a real exchange. Three questions follow, and the answers are rarely in the product documentation.

Who settles the contract? If the issuer hedged with actual shares, it holds a position that can be sold. If it did not, it owes holders a payout it may have to fund from its own balance sheet. The hedge, or the lack of one, determines whether holders are paid in full.

On what price source? A contract that settles against a first-day open, a closing print, a volume-weighted average or the issuer's own discretion pays out very differently, especially in an IPO with a volatile first session. The reference price should be named in advance, sourced independently and published through a data feed that anyone can audit.

What happens to holders who wanted the shares? A backed holder may convert or receive distributed shares subject to lockup. A synthetic holder gets cash, if the issuer chooses to pay, and no ownership.

Institutional allocators should ask for all three answers in writing before buying, because the answers are invisible while the market is rising and decisive when it is not.

What institutions should do now

Treat the checklist as a gating item, not a marketing review. Score every tokenized private asset product on the five points, record the score, and set position limits by structure type: backed issuances can sit alongside other private holdings, while synthetics belong in a derivatives bucket with matching risk limits.

Demand machine-readable evidence where possible. Reserve attestations, holder counts and transfer-restriction logic should be queryable, not buried in a slide deck. The products that earn institutional capital will be those where the claim, the custody and the data are all verifiable on the same ledger.

Commertize's view is that digital capital markets win allocations by being clear about what each instrument is. A token should tell a buyer, in the contract and in the data, whether they own the asset or hold a bet on it. Products that make that distinction obvious will gain share, and those that blur it will spend their time explaining themselves after something breaks.

Source: https://www.sec.gov/resources-small-businesses/exempt-offerings

Prefer email? Send the offering memo or a short asset summary to deals@commertize.com. We reply within one business day, with no obligation to engage us.